Last reviewed · How we verify

NCT04398069

Hemodynamic Optimisation Guided With Transcranial Doppler in Septic Shock

Status unknown NA Last updated 21 May 2020
What this trial tests

NA trial testing hemodynamic optimisation aiming to achieve normal cerebral perfusion in Trans Cranial Doppler Ultrasonography in Heamodynamic Optimisation in Septic Shock in 24 participants. Status unknown.

Timeline
2 January 2020
Primary endpoint
31 August 2020
30 October 2020

Quick facts

Lead sponsorMongi Slim Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment24
Start date2 January 2020
Primary completion31 August 2020
Estimated completion30 October 2020
Sites1 location across Tunisia

Drugs / interventions tested

Conditions studied

Sponsor

Mongi Slim Hospital

Who can join

18 and older, any sex, with Trans Cranial Doppler Ultrasonography in Heamodynamic Optimisation in Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized, controlled, prospective trial, including ICU patients with Sepsis or septic Shock, at the early phase. patients will be randomized in 2 groups regarding the hemodynamic management and catecholamin doses: * Group 1: standard hemodynamic goals and catecholamin infusion to achieve: mean arterial pressure \> or equal to 65 mmHg and diastolic arterial pressure \> ou equal to 50 mmHg within the first 60 minutes. * Group 2: personalized hemodynamic goals and catecholamin infusion until normal transcranial doppler: IP\<1,2.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Mongi Slim Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04398069.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing